findmyKOL
Clinical trialNCT01317199CompletedPhase 1/PHASE2Interventional

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment143Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Howard University College of Medicine

    Washington D.C., District of Columbia, United States

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Cancer Institute of New Jersey

    New Brunswick, New Jersey, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

High-dose MPXLow-dose MPXMuscadine Plus Grape Skin ExtractPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2011
Primary completion
30 Nov 2015
Completion
30 Nov 2015
Last update posted
2 Apr 2021
Registered enrollment
143
Registry id
NCT01317199
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.